meropenem/sulbactam / Generic mfg. - LARVOL DELTA

mSTARS: mHealth-supported Skills Training for Alcohol-Related Suicidality (clinicaltrials.gov) - P=N/A | N=10 | Not yet recruiting | Sponsor: Duke University | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date

Traceability and Characteristic Investigation of Burkholderia Gladioli Bloodstream Infection in Patients with Hematologic Malignancies (ASH 2023) - "Antibiotic susceptibility tests revealed that the clinical strains were susceptible to cefazoxime, ciprofloxacin, levofloxacin, trimethoprim/sulfamethoxazole, cefalexin, cefoperazone/sulbactam, meropenem, imipenem, piperacillin/tazobactam, amikacin, tobramycin, minocycline hydrochloride, tigecycline and resistant to polymyxinB, ampicillin, cefazolin, cefuroxime, aztreonam, and cefoxitin. Foodborne B. gladioli strains in this study exhibited low toxicity and high thermal stability and caused opportunistic bloodstream infections of hematologic malignant patients in immunodeficient states, which deserves our attention. Its special biological characteristic might be attributed to whole and partial loss of toxigenic gene clusters. Clinical B gladioli strains are resistant to polymyxinB, but the standard B gladioli strain and lethal B gladioli strain are susceptible to it, indicating acquired resistance during colonization and empirical antibiotic therapy."

Clinical • Cystic Fibrosis • Febrile Neutropenia • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Neutropenia • Oncology • Primary Immunodeficiency • Respiratory Diseases

Effect of Meropenem, Sulbactam, and Colistin Combinations on Resistance Gene Expression in Multidrug-Resistant A. baumannii Clinical Isolates from Panama. (PubMed, Antibiotics (Basel)) - "Therefore, this study offers a new perspective on how rational combinations of clinically used antibiotics have the potential to modulate gene expression and contribute to the control of MDR strains, indicating that high-dose combination therapy with sulbactam and colistin could offer improved efficacy in treating multidrug resistant Acinetobacter baumannii infections."

Journal • Infectious Disease

Synergistic activity of meropenem and sulbactam against carbapenem-resistant Acinetobacter baumannii. (PubMed, Indian J Pharmacol) - "In the current checkerboard assay, we observed potential synergistic activity between meropenem and sulbactam against CRAB isolates which indicates that this combination can be an appealing strategy in the treatment of nosocomial infections caused by CRAB isolates."

Journal • Infectious Disease

mSTARS: mHealth-supported Skills Training for Alcohol-Related Suicidality Phase 3 (clinicaltrials.gov) - P=N/A | N=35 | Not yet recruiting | Sponsor: Duke University | Trial completion date: Aug 2027 ➔ Dec 2027

Trial completion date

mSTARS: mHealth-supported Skills Training for Alcohol-Related Suicidality (clinicaltrials.gov) - P=N/A | N=10 | Not yet recruiting | Sponsor: Duke University | Trial completion date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date

Clinical and genomic insights into Acinetobacter parvus: A rare pathogen with low antibiotic resistance and potential clinical implications. (PubMed, J Microbiol Immunol Infect) - "This study sheds light on the clinical potential of Acinetobacter parvus, particularly in immunocompromised patients. While its low resistance profile allows for effective treatment, its ability to cause infections warrants further attention."

Journal • Infectious Disease

Real-world efficacy and safety of cefepime for pediatric community-acquired pneumonia: a propensity score-matched study. (PubMed, Front Cell Infect Microbiol) - "This study aimed to evaluate the real-world clinical efficacy and safety of cefepime in treating pediatric community-acquired pneumonia (CAP), comparing it with other broad-spectrum antibiotics, including cefoperazone-sulbactam and meropenem, using a propensity score-matched design. These findings support cefepime as a viable empiric therapy option, particularly in settings with limited microbiological diagnostics. Further studies are needed to confirm these results and optimize dosing strategies for pediatric populations."

Journal • Real-world evidence • Retrospective data • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases

Comparative in vitro activity of sulbactam with avibactam or durlobactam against carbapenem-resistant Acinetobacter baumannii. (PubMed, JAC Antimicrob Resist) - "Standardized susceptibility testing by broth microdilution was performed to determine MICs for imipenem, meropenem and sulbactam alone, and for combinations including sulbactam/avibactam, sulbactam/durlobactam, sulbactam/avibactam/meropenem, sulbactam/avibactam/imipenem, sulbactam/durlobactacm/meropenem and sulbactam/durlobactam/imipenem. Carbapenem combinations were more active than combinations without a carbapenem against isolates with PBP3 mutations. These data show that imipenem potentiates sulbactam-based combinations to a greater extent than meropenem; however, future studies are needed to define how these data should be applied in clinical practice."

Journal • Preclinical

mSTARS: mHealth-supported Skills Training for Alcohol-Related Suicidality (clinicaltrials.gov) - P=N/A | N=10 | Not yet recruiting | Sponsor: Duke University | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date

Rothia mucilaginosa: A Surprising Culprit of Pneumonia in an Absolute Immunocompetent Patient. (PubMed, J Assoc Physicians India) - "R. mucilaginosa is a significant pathogen causing pneumonia in diverse patient groups. Without formal treatment guidelines, diagnosis relies on clinical experience. Early detection and appropriate antibiotic therapy are crucial for effective management."

Journal • Cardiovascular • Chronic Cough • Cough • Infectious Disease • Pneumonia • Respiratory Diseases • CRP

Comparative evaluation of five β-Lactamase inhibitors in combination with β-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro. (PubMed, BMC Infect Dis) - "the combination of tebipenem and relebactam shows the most potent activity against MDR-TB isolates. In addition, the Ser111Arg and Asn213Thr substitution of BlaC may be associated with increased susceptibility of MDR-TB isolates to meropenem in thepresence of clavulanate and sulbactam."

Journal • Preclinical • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Multicenter Longitudinal Quality Assessment of MS-Based Proteomics in Plasma and Serum. (PubMed, J Proteome Res) - "In a joint effort, eight proteomics laboratories belonging to the MSCoreSys initiative including the CLINSPECT-M, MSTARS, DIASyM, and SMART-CARE consortia performed a longitudinal round-robin study to assess the analysis performance of plasma and serum as clinically relevant samples...Overall, 71 proteins are reproducibly detectable in all setups in both serum and plasma samples, and 22 of these proteins are FDA-approved biomarkers, which are reproducibly quantified (CV < 20% with label-free quantification). In total, the round-robin study highlights a promising baseline for bringing MS-based measurements of serum and plasma samples closer to clinical utility."

Journal

Pharmacokinetic/pharmacodynamic analysis of sulbactam against Acinetobacter baumannii pneumonia: establishing in vivo efficacy targets in the epithelial lining fluid. (PubMed, JAC Antimicrob Resist) - "Sulbactam (dosed as ampicillin-sulbactam) bronchopulmonary PK was assessed in the neutropenic murine pneumonia model...Median (IQR) %fT > MIC required to achieve 1-log kill in isolates resistant to both sulbactam and meropenem was 47.51 (39.7-54.2)...Based on the ELF assessment, the maximum FDA approved dose of sulbactam (1 g q6h 0.5h infusion) provided >90% PTA for isolates with sulbactam MIC only up to 2 mg/L. Nevertheless, sulbactam 3 g q8h for 4 hours of infusion achieved higher PTA and conferred additional benefit against sulbactam-susceptible/intermediate isolates."

Journal • PK/PD data • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

Genetic Characterization of Multidrug-Resistant Acinetobacter baumannii and Synergy Assessment of Antimicrobial Combinations. (PubMed, Antibiotics (Basel)) - "The activities of antimicrobial combinations including tigecycline, ampicillin/sulbactam, meropenem, levofloxacin, and colistin were evaluated using checkerboard and time-to-kill assays on isolates with different susceptibility profiles and genetic characteristics. Synergistic activity was observed with meropenem-colistin and levofloxacin-ampicillin/sulbactam combinations in the checkerboard method, but not in the time-to-kill assays. These discrepancies among both methods indicate that further studies are needed to determine the best therapeutic combination for treating infections by A. baumannii."

Journal • Infectious Disease

Salmonella typhimurium infection after lingual mucosa graft ureteroplasty: a case report and review of literature. (PubMed, BMC Infect Dis) - "This case suggests that urinary tract infection may not be the most crucial factor influencing the survival of autologous tissue grafts. With aggressive antimicrobial therapy according to sensitivity, the survival of autologous tissue grafts remains unaffected. Our case may offer valuable insights on urinary tract infections in the context of autologous tissue transplantation for ureteral augmentation."

Journal • Review • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Nephrology • Septic Shock • Transplantation

Synergistic effects of bacteriophage cocktail and antibiotics combinations against extensively drug-resistant Acinetobacter baumannii. (PubMed, BMC Infect Dis) - "The findings suggested that the bacteriophage cocktail is an effective tool in combating A. baumannii biofilms, with its efficacy depending on the concentration. Combining antibiotics with the bacteriophage cocktail improved the inhibition and removal of biofilms, indicating a promising strategy for managing A. baumannii infections. These results contribute to our understanding of biofilm dynamics and the potential of bacteriophage cocktails as a novel therapeutic approach to combat antibiotic-resistant bacteria."

Journal • Infectious Disease

Tumor complete response and pyogenic liver abscess secondary to concurrent microwave ablation plus atezolizumab and bevacizumab in liver cancer: a case report. (PubMed, J Gastrointest Oncol) - "The patient was diagnosed with PLA complicated by septic shock, and due to recurrent fever, multiple courses of antibiotics (imipenem/cilastatin sodium, cefoperazone/sulbactam, meropenem, respectively) were administered in combination with five percutaneous drainages over the next 90 days. The use of multiple courses of antibiotics over a prolonged period did not appear to influence the effectiveness of atezolizumab and bevacizumab. Further studies are, however, needed to substantiate this finding."

Journal • Gastrointestinal Cancer • Hepatology • Liver Cancer • Oncology • Septic Shock • Solid Tumor • CRP

In vitro elution of amikacin, cefazolin, gentamicin, ampicillin/sulbactam, and meropenem from a commercially available calcium sulfate delivery kit. (PubMed, Front Vet Sci) - "Most of the antibiotic elution occurred within the first week and was maintained above the MIC of commonly encountered isolates. This information may be useful for clinical decision making for treatment of local infections encountered in practice."

Journal • Preclinical • Infectious Disease

Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. (PubMed, Front Cell Infect Microbiol) - "Moreover, new drugs such as durlobactam and cefiderocol have substantial therapeutic capabilities and may be effective salvage treatments...Despite its significant nephrotoxicity, colistin is considered a primary treatment and is often used in combination with antimicrobials, such as tigecycline, ampicillin-sulbactam, meropenem, or fosfomycin. The Infectious Diseases Society of America (IDSA) has deemed high-dose ampicillin-sulbactam, which is typically combined with high-dose tigecycline, polymyxin, and other antibacterial agents, the best option for treating serious CRAB infections. A rational combination of drug use and the exploration of new therapeutic drugs can alleviate or prevent the effects of CRAB infections, shorten hospital stays, and reduce patient mortality."

Journal • Review • Infectious Disease

Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations. (PubMed, J Antimicrob Chemother) - "Sulbactam standard dose is a valuable regimen across sulbactam-susceptible isolates while the high-dose extended-infusion provides additional benefit against sulbactam-intermediate isolates. Given that most of the sulbactam-resistant A. baumannii isolates are meropenem-resistant, high-dose prolonged-infusion regimens are not expected to be effective as monotherapy against infections due to these isolates."

Journal • PK/PD data • Infectious Disease • Pneumonia • Respiratory Diseases

Insights and Opinions of Critical Care Healthcare Professionals in the Management of Carbapenem-resistant Enterobacteriaceae Cases and Antibiotic-Resistant Infections in the Intensive Care Unit Setting: A Survey-Based Approach. (PubMed, J Assoc Physicians India) - "The article concludes with a discussion on the antibiotics used in response to CRE cases, reporting that critical care HCP considers MSE with high efficacy and safe antibiotic combination and was used as both monotherapy and in combination with other antibiotics. The survey highlights the need for exploring and better understanding the role of MSE in the management of CRE infections, especially in NDM-1."

Journal • Critical care • Infectious Disease • Pneumonia

In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece. (PubMed, J Antimicrob Chemother) - "Apramycin combinations may have potential as a treatment option for XDR/pandrug-resistant (PDR) A. baumannii infections and warrant validation in the clinical setting, when this new aminoglycoside is available for clinical use."

Combination therapy • Journal • Preclinical • Infectious Disease

'Rules of engagement': Does competition drive engagement in faculty development. (PubMed, Clin Teach) - "Competition may not provide a motivation for HCPs to engage in FD and may be a barrier. Providing collaboration opportunities, faculty coaching and the chance to develop new skills could enhance engagement."

Journal

Acinetobacter Non-baumannii Species: Occurrence in Infections in Hospitalized Patients, Identification, and Antibiotic Resistance. (PubMed, Antibiotics (Basel)) - "This study provides important new insights into the methods of identification, occurrence, species distribution, and antibiotic resistance traits of clinical Anb isolates."

Journal • Infectious Disease • Nephrology